The Value of Moderna's mRNA Technology Is Obscured by Fears of a Hostile US Regulatory Environment
Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...
GSK resolves patent lawsuit against Pfizer over RSV vaccines
British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...
Healthcare: Policy Uncertainty Is Countered by Interest in Defensive Stocks
Moderna, Baxter, and Pfizer are our top healthcare picks.
US FDA declines to approve Aldeyra's eye disease drug
The U.S. Food and Drug Administration has declined to approve Aldeyra Therapeutics' treatment for dry eye disease, the ...
Dispute Over Covid Vaccines Casts Doubt On Clover Bio Recovery
It reported revenues of 38.41 million yuan in the first half of 2024 and a net loss of 903 million yuan, hit by falling ...
Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna
Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...